Clinical Trials Currently Recruiting Patients:

Psoriasis (Injectable Medication)
Requirements: Adult patients (18-55) with moderate to severe psoriasis.  Must not have used biologic medications in the last 12 months and meet all other exclusion criteria.  Biologic medications include: Amevive (alefacept), Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), and Stelara (ustekinumab).
Duration: 4 visits over 6 months plus 2 follow-up phone calls at 9 months and 1 year.
Incentive: $25/visit and FDA-approved study medication Humira (adalimumab), laboratory testing, and cardiovascular function testing provided at no cost.

Sponsor: Supported by Abbott

Study Coordinator: Erika Hanami

Click here for a printable flyer.

Hidradenitis Suppurativa (Injectable Medication)
Requirements: Adult patients (18+) with moderate to severe HS.  Must not have been treated with Humira, Enbrel, Remicade, Tysabri, or Raptiva in the past.  Must not be pregnant, trying to get pregnant, or nursing.
Duration: Study will last 36 weeks and require 13 study visits.
Incentive: $50/visit. Study medication, study-related exams, and lab tests will be provided at no cost.

Sponsor: Pfizer

Study Coordinator: Erika Hanami

PSOLAR Psoriasis Registry

Requirements: Patients with chronic plaque psoriasis who are on systemic treatments such as PUVA, MTX, and Soriatane, or biologics, especially Remicade and Stelara.
Duration: Incorporated into your regular office visits every 6 months for up to 8 years.
Incentive: $45/visit. This study only requires you to answer questions and fill out questionnaires.

Sponsor: Centocor

Study Coordinator: Phil Lee

ESPRIT Psoriasis Registry
Requirements: Psoriasis patients who are beginning to take Humira.
Duration: Incorporated into your regular office visits every 6 months for up to 10 years.
Incentive: None. This study only requires you to answer questions and fill out questionnaires.

Sponsor: Abbott

Study Coordinator: Phil Lee

Your Physician:
Aida Lugo-Somolinos, MD
Link to Dr. Lugo-Somolinos' Research